Targeting the Complement Cascade: A Novel Therapeutic Strategy for Metastatic Melanoma [ 2016 - 2018 ]

Research Grant

Researchers: Dr Barbara Rolfe (Principal investigator) ,  A/Pr Trent Woodruff ,  Dr Glen Boyle

Brief description The incidence of melanoma is increasing world-wide, and Queensland has the highest rate of melanoma in the world. Despite advances in treatment, the 3-year survival rate for metastatic melanoma remains extremely low. This project builds on our recent research demonstrating a role for a key component of the innate immune system (complement C3a) in melanoma growth. Specifically we seek to investigate the potential of C3a as a therapeutic target for metastatic melanoma.

Funding Amount $AUD 561,868.40

Funding Scheme Project Grants

Notes Standard Project Grant